Cretostimogene grenadenorepvec is under clinical development by CG Oncology and currently in Phase III for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase III drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Cretostimogene grenadenorepvec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cretostimogene grenadenorepvec overview
CG-0070 is under development for the treatment of high grade non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer, metastatic bladder cancer, metastatic urothelial cancer and other solid tumors. The drug candidate is administered intravesically and intratumoral routes. CG-0070 is the first armed oncolytic virus therapy. It is engineered to secrete GM-CSF, an immune-stimulating hormone, which also serves as the adjuvant in GVAX cancer immunotherapy platform. It was under development for ovarian cancer, glioblastoma multiforme, lung cancer and head and neck cancer.
CG Oncology overview
CG Oncology (CG Oncology) is a biopharmaceutical company that develops novel immunotherapies for the treatment of cancers. The company is investigating CG0070, oncolytic immunotherapy used alone or in combination with immune checkpoint modulators, to treat muscle and non-muscle invasive bladder cancer, metastatic bladder cancer, solid tumors and CG0161; an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein) antibody, against oncology indications. It utilizes oncolytic immunotherapy technology where genetically modified viruses are used to kill cancer cells and generate anti-tumor immune responses. CG Oncology is headquartered in Irvine, California, the US.
For a complete picture of Cretostimogene grenadenorepvec’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
